Raykov Rosty 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Fennec (FENC) Director Rosty Exercises Options, Sells Shares
What Happened
- Director Rosty exercised 15,598 stock options at an exercise price of $2.45 per share, costing $38,215, and a related disposition tied to that exercise is reported. Separately, he sold 10,349 shares in an open‑market sale at $7.76 per share, receiving $80,308. The filing notes the exercise and related transactions were made under a 10b5‑1 trading plan and that some shares were sold to satisfy tax withholding obligations.
Key Details
- Transaction date: 2026-02-02
- Option exercise (acquired): 15,598 shares @ $2.45 = $38,215 (footnote: exercised under a 10b5‑1 plan adopted 9/19/2025)
- Open‑market sale (disposed): 10,349 shares @ $7.76 = $80,308
- Footnote indicates shares were sold to satisfy tax obligations on the option exercise
- Shares owned after the transactions: not specified in the supplied summary of the filing
- Filing date matches the transaction date (no late filing indicated in the provided data)
Context
- This was an option exercise (an acquisition) combined with share sales. Selling shares to cover taxes or immediately after exercising options is a common administrative action (often called a cashless exercise/tax withholding) and does not necessarily indicate a change in the insider’s view of the company. The presence of a 10b5‑1 plan means the exercise and sales were executed under a prearranged trading plan adopted on September 19, 2025.
Insider Transaction Report
Form 4
Raykov Rosty
Director
Transactions
- Exercise/Conversion
Common shares
[F1]2026-02-02$2.45/sh+15,598$38,215→ 108,826 total - Sale
Common shares
[F2]2026-02-02$7.76/sh−10,349$80,308→ 98,477 total - Exercise/Conversion
Stock Options
[F3]2026-02-02$2.45/sh−15,598$38,215→ 1,602,988 totalExercise: $2.45From: 2016-07-05Exp: 2026-07-05→ options (15,598 underlying)
Footnotes (3)
- [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.
Signature
/s/ Rosty Raykov|2026-02-02